Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02152020 · ClinicalTrials.gov registry record
Patient-Centered Acupuncture for Pain (PCAP)
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 36
- Enrollment target
NCT02152020: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02152020 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02152020 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
Study Summary
The objective of this study is to find out if acupuncture can improve the management of pain in cancer patients when used as part of a treatment plan that includes conventional pain medications. The investigators will enroll 36 cancer patients at Abramson Cancer Center and Penn Cancer Network sites. Participants will be enrolled in either the Conventional Pain Management group or Integrative Pain Management group.
Interventions
- BEHAVIORAL Survey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-01 |
What the finished NCT02152020 record still lists
NCT02152020 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Survey is the first listed.
NCT02152020 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02152020 about?
NCT02152020 is a clinical study titled "Patient-Centered Acupuncture for Pain (PCAP)". The objective of this study is to find out if acupuncture can improve the management of pain in cancer patients when used as part of a treatment plan that includes conventional pain medications. The investigators will enroll 36 cancer patients at Abramson Cancer Center and Penn Cancer Network sites....
What is the current status of trial NCT02152020?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2014-05. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02152020?
The interventions under investigation include: Survey (BEHAVIORAL).
Who is sponsoring clinical trial NCT02152020?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia